INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Elevance Health, Inc. - ELV

Core Viewpoint - Elevance Health, Inc. is under investigation for potential securities fraud and unlawful business practices following a notification from the Centers for Medicare & Medicaid Services regarding sanctions on its Medicare Advantage plans [1][2]. Group 1: Investigation Details - Pomerantz LLP is investigating claims on behalf of Elevance investors, focusing on possible securities fraud or unlawful business practices by the company and its officers [1]. - The investigation was prompted by a recent disclosure from Elevance about sanctions from CMS, which may affect its Medicare Advantage-Prescription Drug plans [2]. Group 2: CMS Sanctions - On March 2, 2026, Elevance announced that CMS intends to impose sanctions that would suspend enrollment of Medicare beneficiaries into its MA-PD plans and halt certain communications with these beneficiaries [2]. - The sanctions are related to alleged noncompliance with Medicare Advantage risk adjustment data submission requirements for services prior to April 3, 2023, and are set to take effect on March 31, 2026, unless resolved [2]. - Following this announcement, Elevance's stock price dropped by $25.93, or 8.1%, closing at $294.07 per share on the same day [2].